Phagenesis Extends Series B Financing to $17M

Phagenesis, a Manchester, UK-based developer of solutions for the treatment of dysphagia, has expanded its Series B financing to $17m.

The company had raised €7m in Series B (read here) and £2m in a Series A financing in 2010 (read here).

The company intends to use the funds to launch the Phagenyx® treatment, which received CE Mark in 2012, in new territories and to expand clinical testing in new patient groups.

Led by Daniel Green, CEO, Phagenesis has developed a treatment for Dysphagia, the inability to swallow safely, a debilitating condition that affects about half of stroke patients.
It involves an electrical stimulus to the oropharynx (a region of the back of the throat) for 10 minutes a day for three consecutive days.



Join the discussion